A Phase 1 Dose-Escalation and Phase 2 Randomized, Open-Label Study of Nivolumab and Veliparib in Combination With Platinum Doublet Chemotherapy in Subjects With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I/II
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Nivolumab (Primary) ; Veliparib (Primary) ; Carboplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AbbVie
- 17 Jul 2017 Planned End Date changed from 1 Jul 2021 to 23 Jun 2018.
- 26 Jan 2017 Planned number of patients changed from 184 to 192.
- 26 Jan 2017 Planned End Date changed from 1 Mar 2019 to 1 Jul 2021.